Patents by Inventor Peter Sheldrake

Peter Sheldrake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250029046
    Abstract: A method and system for adjusting properties of another system based on a risk score associated with an entity, using a framework comprising a server having a risk determinator, an API, and storage for storing a risk profile associated with the entity and a risk property associated the risk profile. The method is performed by the server, and comprises obtaining, from the storage, the risk profile associated with the entity, where the risk profile is generated by a risk determinator, and based on at least one risk property. The risk determinator generates the risk score associated with the entity based on the risk profile, and the server determines an adjustment to the properties of the system based on at least the risk score. The adjustment is output, through the API to the other system.
    Type: Application
    Filed: July 16, 2024
    Publication date: January 23, 2025
    Inventors: Anthony Robert PEPPER, Neil Tony LARKINS, Jack Alexander CHAPMAN, James Peter SHELDRAKE, Thomas HAZELL
  • Patent number: 11897877
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 13, 2024
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20220402912
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 13, 2021
    Publication date: December 22, 2022
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Patent number: 11046688
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 29, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20200165241
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 10, 2019
    Publication date: May 28, 2020
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Patent number: 10479788
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 19, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Patent number: 10188642
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 29, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming Jack Cheung, Butrus Atrash, Peter Sheldrake
  • Publication number: 20180141944
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 24, 2018
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20180117032
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming Jack Cheung, Butrus Atrash, Peter Sheldrake
  • Patent number: 9895364
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 20, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
  • Patent number: 9890157
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: February 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Patent number: 9834552
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: December 5, 2017
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20160296514
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 14, 2016
    Publication date: October 13, 2016
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
  • Patent number: 9409907
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: August 9, 2016
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20160222009
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 4, 2016
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20160220570
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 4, 2016
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Patent number: 9334286
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 10, 2016
    Assignee: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
  • Publication number: 20150239884
    Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 27, 2015
    Applicant: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
  • Publication number: 20150218181
    Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 6, 2015
    Applicant: Cancer Research Technology Limited
    Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake